SHASUNPHAR

Shasun Pharmaceuticals Limited has informed the Exchange that there was a fire accident at New production block during trial & commissioning in Cuddalore API facility on November 16, 2015. Company regrets to inform the sad demise of one worker in the accident. One more injured employee has been admitted in the hospital for treatment. The Company has informed the government authorities about the same and investigating the root cause of the accident.The damage on account of fire is being assessed for which the company has adequate insurance cover. However there will not be any significant loss o

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 16, 2015 titled "Shasun Pharmaceuticals receives USFDA approval for Carisoprodol Tablets".

Strides Arcolab Limited has informed the Exchange that as approved by the Board of Directors of the Strides Acrolab Limited by a resolution passed on November 05, 2015, has fixed Record Date as November 19, 2015 for the purpose of determining the names of the shareholders of Shasun Pharmaceuticals Limited who will be entitled to shares in the Strides Acrolab Limited (as consideration under the Scheme of the Amalgamation), in the exchange ratio of 5 (five) equity shares of Rs. 10/- each of Strides for every 16 (sixteen) equity shares of Rs. 2/- each held in the Shasun Pharmaceuticals Limited.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 27, 2015 titled "Shasun Pharmaceuticals Ltd announces strong Q2 FY 16 results".

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2015.

Shasun Pharmaceuticals Limited has informed the Exchange that as per the provisions of the Company's Code for Prevention of Insider Trading, the trading window for designated employees of the Company closed from September 10, 2015 to October 29, 2015 (both days inclusive).

Shasun Pharmaceuticals Limited has informed the Exchange that the Board at its meeting held October 13, 2015 has allotted 31,600 equity shares of the face value of Rs.2 each under the ESOP Scheme.The paid up share capital of the Company has increased from Rs.13,44,47,704/ - consisting of 6,72,23,852 equity shares to Rs.13,45,10,904/- consisting of 6,72,55,452 equity shares.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on August 12, 2015.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of voting results of Annual General Meeting of the Company held on August 12, 2015, along with a copy of Scrutinizer's Report pursuant to Clause 35A of the Listing Agreement.

Shasun Pharmaceuticals Limited has informed the Exchange that The Board at its meeting held on July 30, 2015 has approved the following: 1. Interim Dividend of 50% (Rs. 1 per share) on the equity shares of face value of Rs.2/- each.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 30, 2015 titled "Shasun Pharmaceuticals Ltd announces Q1 FY16 results".

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Jun-2015.

Shasun Pharmaceuticals Limited has informed the Exchange that the Hon'ble High Court of Judicature of Madras has sanctioned the Scheme of Amalgamation with Strides Arcolab Limited pursuant to its order dated June 16, 2015. Certified copy of order received on July 22, 2015.The Scheme of Amalgamation will be effective on receipt of the approval from Hon'ble High Court of Bombay, Foreign Investment Promotion Board and other approvals as may be required and on filing of a copy of the order of Hon'ble High Courts with respective Registrar of Companies.

Shasun Pharmaceuticals Limited had informed the Exchange that the Share Transfer Books / Register of Members of the Company will be closed on August 6, 2015. The Annual General Meeting of the Company will be held on August 12, 2015. The Company has now informed the Exchange that the book closure date for Annual General Meeting and for the purpose of interim dividend is August 6, 2015. (purpose revised)

Shasun Pharmaceuticals Limited has informed the Exchange that as per the provisions of the Company's Code for Prevention of Insider Trading, the trading window for designated employees of the Company is closed from June 10, 2015 to August 03, 2015 (both days inclusive).

Shasun Pharmaceuticals Limited has informed the Exchange that the Share Transfer Books / Register of Members of the Company will be closed on August 6, 2015. The Annual General Meeting of the Company will be held on August 12, 2015.

Shasun Pharmaceuticals Limited has submitted to the Exchange vide letter dated June 10, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sequent Scientific Limited has submitted to the Exchange vide letter dated June 9, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on June 08, 2015 has approved the conversion of 71,00,000 convertible warrants into equity shares of the Company, which were issued on May 30, 2014 to M/s. Sequent Scientific Limited, Mumbai, on preferential basis at a price of Rs 110 per share including premium of Rs 108 per share.

Shasun Pharmaceuticals Limited has submitted to the Exchange, vide letter dated June 03, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Morgan Stanley Asia (Singapore) Pte has submitted to the Exchange vide letter dated June 3, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in the equity shares will be closed for Directors and designated employees of the Company from June 02, 2015 to June 10, 2015 (both days inclusive).

Shasun Pharmaceuticals Limited has informed the Exchange that the requirements of the SEBI (Prohibition of Insider Trading) Regulations, 2015 ("the Regulations") we hereby inform you as follows: 1. Pursuant to the requirements of regulations 8(2) of the Regulations, the Company have formulated & Published on its website www.shasun.com the "Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information, " a copy of which is enclosed herewith for your record. 2. Pursuant to the requirements of regulation 9(1) of the Regulations, the Company has formulated a C

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 30, 2015 has approved and appointed Mrs. Taru Mayur as Director of the Company with effect from April 30, 2015.

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Auditors Report for the period ended 31-Mar-2015.

Shasun Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in the equity shares will be closed for Directors and designated employees of the Company from April 23, 2015 to May 01,2015 (both days inclusive).

Shasun Pharmaceuticals Limited has informed the Exchange that the Company had completed the sale of 74,00,000 equity shares held in M/s. Alivira Animal Health Limited to M/s Sequent Scientific Limited.

Shasun Pharmaceuticals Limited has informed the Exchange regarding declaration of results of postal ballot as per Clause 35A along with Scrutinizer Report.

Shasun Pharmaceuticals Limited has informed the Exchange that further to the Company's letter dated February 06, 2015, the Court Convened meeting of the equity shareholders of the Company was held on March 12, 2015 as ordered by the Hon'ble High Court of Judicature at Madras in its order dated January 09, 2015 in Company Application No. 33 of 2015 in connection with the Scheme of Amalgamation of Shasun Pharmaceuticals Limited with Strides Arcolab Limited pursuant to Sections 391 to 394 of Companies Act, 1956 and other applicable provisions of the Companies Act, 2013. This is to inform you t

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of result of Postal Ballot under Clause 35A of the Listing Agreement.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the Postal Ballot Notice, pursuant to Section 110 of the Companies Act, 2013.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the Court Convened Meeting of the Equity Shareholders and Postal Ballot and E-voting.

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 5, 2015 has approved the following: 1) Pro. Indira J Parikh, Independent Director, has resigned from the Board with effect from February 05, 2015. 2) Postal Ballot for obtaining approval of the public shareholders for the merger scheme. 3) Postal ballot for obtaining certain approvals of the shareholders.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 5, 2015 with respect to the financial results for the quarter ended December 31, 2014.

Shasun Pharmaceuticals Limited has submitted to the exchange the consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the Company has fixed January 30, 2015 as the cut-off date, for the purpose of ascertaining the list of Members eligible to vote on the proposed Extraordinary General Meeting of the Company.

Shasun Pharmaceuticals Limited has informed the Exchange that the Company has fixed January 30, 2015 as the cut-off date, for the purpose of ascertaining the list of Members eligible to vote on the proposed postal ballot for the purpose of Amalgamation.

Shasun Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in the equity shares will be closed for Directors and designated employees of the Company from January 24, 2015 to February 6, 2015 (both days inclusive).

Jitesh Devendra has submitted to the Exchange, vide letter dated January 19, 2015 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange vide letter dated January 20, 2015 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange, vide letter dated December 31, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange, vide letter dated December 31, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011.

Ambematha Securities has submitted to the Exchange, vide letter dated December 31, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Chayadeep Properties Private Limited & Pronomz Ventures LLP have submitted to the Exchange, vide letter dated December 31, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 13, 2014, titled "Successful completion of US FDA inspection".

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the trading window for dealing in the equity shares will be closed for Directors and designated employees of the Company from October 27, 2014 to November 07, 2014 (both days inclusive).

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors held on September 29, 2014 has approved a scheme of amalgamation between the Company and Strides Arcolab Limited wherein, wherein, the Company will amalgamate with Strides Arcolab Limited. The Scheme of amalgamation is subject to various statutory and regulatory approvals, as may be applicable.Further the Company has submitted a copy of the press release dated September 29, 2014, titled " Strides Arcolab and Shasun Pharmaceuticals combine to accelerate strategy and growth".

Morgan Stanley Asia (Singapore) Pte. has submitted to the Exchange vide letter dated September 04, 2014 a copy of disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011.